Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Reservork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Substitute for for	m 1449B	/PTO	Complete if Known		
INFORMATION DISCLOSURE					Application Number	10/817,454	
STATEMENT BY APPLICANT				CANT	Filing Date	04/01/2004	
					First Named Inventor	David Alan Campbell	
					Group Art Unit	1646	
(use as many sheets as necessary)					Examiner Name		
Sheet		1	of	1	Attorney Docket Number	063391-1802	

U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,		
	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
			<u> </u>	·				

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. <sup>1</sup>			Fore Office 3	eign Patent D Number.4	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		_								
		<u> </u>		_	•	·		1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
JR	A1	Clontech Catalog: Innovative Tools to Accelerate Discovery. 6-Carboxyfluorescein-ON™ phosphoramidite user manual. PT-3354-1 (PR95959), Published May 3, 1999.	
JR	A2	Madoyan et al., "Affinity labeling of tryptophanyl-tRNA synthetase with mesitoyl-amp." FEBS Letters, 123: 156-160, January 1981.	
JR	A3	Manabe et al., Preparation of glycosylated amino acid derivatives for glycoprotein synthesis by in vitro translation system.* Bioorganic & Medicinal Chemistry, 10:573-581, 2002	
JR	A4	International Search Report for PCT Application No. PCT/US2004/10075 , 200 \$	
		,	

Examiner Signature	/Jezia Riley/	Date . Considered	02/18/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

JUL 16 2004

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE d to respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995

Substitute for form 1449B/PTO PARTY

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/817,454 **Filing Date** 04/01/2004 **First Named Inventor** David Alan Campbell **Group Art Unit Examiner Name** 

(use as many sheets as necessary)

Sheet of **Attorney Docket Number** 063391-1802

Examiner Initials*		U.S. Patent	Document		D.1. (D.1	Pages, Columns, Lines,
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
JK	A1	4,415,655		De Castro et al.	11-15-1983	
	A2	4,481,094		Fernandez de Castro et al.	11-06-1984	
	A3	4,865,707		Karger et al.	09-12-1989	
	A4	4,946,794		Berube	08-07-1990	
	A5	5,215,970		Datema et al.	06-01-1993	
	A6	6,008,373		Waggoner et al.	12-28-1999	
	A7	6,043,060		Imanishi .	03-28-2000	•
JK	A8	6,255,292		Liang	07-03-2001	
			<del></del>			

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite No.1				. Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	Γ		
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	T6		
JR	A9	wo	00/011208		University of Washington	03-02-2000				
JR	A10	wo	01/77668		The Scripps Research Institute	10-18-2001				
JR .	A11	wo	01/77684		The Scripps Research Institute	10-18-2001				
JR_	A12	wo	03/079014		Pharmacia Groningen BV	01-30-2003				
·				<del></del>				ļ		
								<del> </del>		

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>						
JR	A13	Bergseid et al., Small molecule-based chemical affinity system for the purification of proteins. Biotechniques (2000) 29(5):1126-1133							
JR	A14	Bishop et al., Magic bullets for protein kinases. Trends Cell Biol (2001) 11(4):167-172							

Examiner Signature	/Jezia Riley/	*	Date Considered	02/18/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emparor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language

Approved for use through 10/31/2002. OMB.0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	or form 1449B	/PTO	Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/817,454		
STATEMENT BY APPLICANT			CANT	Filing Date	04/01/2004		
				First Named Inventor	David Alan Campbell		
				Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Sheet	2	of	4	Attorney Docket Number	063391-1802		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>
JR	A15	Clauser, et al., Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc. Natl. Acad. Sci. USA (1995) 92:5072-76	
JR	A16	Daniel, SM et al., FastTag™ Nucleic Acid Labeling System: A Versatile Method for Incorporating Haptens, Fluorochromes and Affinity Ligands into DNA, RNA and Oligonucleotides. Biotechniques (1998) 24(3), 484-489	
JR	A17	De Leenheer, et al., Applications of isotope dilution-mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology. Mass Spectrom. Rev. (1992) 11:249-307	
JR	A18	Deutscher (ed.), Methods in Enzymology, (1990) vol. 182, pp. 147-238, chapter 12 by Cull and McHenry entitled "Preparation of extracts from Prokaryotes."	
JR	A19	Eisen et al., Cluster analysis and display of genome-wide expression patterns. <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95:14863-14868	
JR	A20	Eng. et al. An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database. J. Am. Soc. Mass Spectrom. (1994) 5:976-989	
JR	A21	Gibson et al., Nonpeptidic $a_y\beta_3$ Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Agnew. Chem. Int. Ed. (2001) 40: 165-169.	
JR	A22	Gottschling et al., Cellular Solid-Phase Binding Assay and Mass Spectrometry for Screening of a4g7 Integrin Antagonists. Bioorg. And Medicinal Chem. Lett. (2001) 11: 2997	
JR	A23	Gygl et al., Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era. Mol. Cell. Blol. (1999) 19:1720-1730	,
. JR	A24	Gygi, et al., Correlation between Protein and mRNA Abundance in Yeast. Mol. And Cell. Biol. (1999) 20:310-319	

	والمراجع		
Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English tanguage Translation is attached.

Approved for use through 10/31/2002. OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/817,454	
				Filing Date	04/01/2004	
				First Named Inventor	David Alan Campbell	
				Group Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	3	of	4	Attorney Docket Number	063391-1802	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ°
JR	A25	Hanks and Hunter, "The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification." FASEB J. (1995) 9(8):576-596	
JR	A26	Kidd et al., Profiling Serine Hydrolast Activities in Complex Proteomes. Biochemistry (2001) 40: 4005-15	-
JR	A27	Kolb et al., Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Agnew Chem. Int. Ed. Engl. (2001) 40: 2004-21	
JR	A28	Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature (1970) 227:680-685	
JR	A29	Lemieux et al. A Fluorogenic Dye Activated by the Staudinger Ligation. J. Am. Chem. Soc. (2003) 125: 4708-4709	
JR	A30	Leon et al., Evaluation of Resins for On-Bead Screening: A Study of Papain and Chymotrypsin Specificity Using Pega-Bound Combinatorial Peptide Libraries. Bioorg. Med. Chem. Lett. (1998) 8: 2997	
JR	A31	Link, et al., Identifying the major proteome components of <i>Haemophilus influenzae</i> type-strain NCTC 8143. Electrophoresis (1997) 18:1314-34	-
JR	A32	Mann and Wilm, Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags. Anal. Chem. (1994) 66:4390-99	

Examiner	/Jezia Riley/	Date	02/18/2007
Signature	, 00224 1120//	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw line through dilation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). °For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B	/PTO		Complete If Known		
	INFORMATION D	ISCLO	SURE	Application Number	10/817,454		
	STATEMENT BY	APPLI	CANT ·	Filing Date	04/01/2004		
			-	First Named Inventor	David Alan Campbell		
				Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Sheet	4	of	4	Attorney Docket Number	063391-1802		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	ť
JR	A33	Orain and Bradley, Solid phase synthesis of trypanothione reductase inhibitors-towards single bead screening. Tetrahedron Lett. (2001) 42: 515-518	
JR	A34	Papanikos et al., <i>o</i> –Ketocarbonyl Peptides: A General Approach to Reactive Resin-Bound Intermediates in the Synthesis of Peptide Isosteres for Protease Inhibitor Screening on Solid Support. J. Am. Chem. Soc. (2001) 123: 2176 2181	-
JR	A35	Porco, Organic Synthesis Using Chemical Tags: The "Third Leg" of Parallel Synthesis. JA Comb. Chem. High Throughput Screening (2000) 3(2) 93-102	
JR	A36	Ross et al., Systematic variation in gene expression patters in human cancer cell lines. Nat. Genet. (2000)24:227-235	
JR	A37	Seo et al., Click Chemistry to Construct Fluorescent Oligonucleotides for DNA Sequencing. J. Org. Chem. (2003) 68: 609-612	
JR	A38	Smith and Bradley, Comparison of Resin and Solution Screening of Methodologies in Combinatorial Chemistry and the Identification of a 100nM Inhibitor of Trypanothione Reductase. J. Comb. Med. (1999) 1: 326-332.	

Examiner Signature	/Jezia Riley/	 Date Considered	02/18/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, <sup>5</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language